Drugs makers to be watched by European Commission
08 July 2009
James Nurton, London
The European Commission will intensify scrutiny of the pharmaceutical industry under antitrust law and monitor originator-generic settlements, it said in a report published today
The Commission’s report is the culmination of a 18-month sector inquiry into why fewer new medicines are brought to the market and why generic entry can be delayed.
The Commission said it will monitor the industry under EU antitrust law and bring cases against specific abuses “where appropriate”.
In particular, it said that originator companies’ use of instruments...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial